Colorado-based Enveda has begun clinical trials of ENV-294, an oral inflammatory agent for the treatment of atopic dermatitis. The drug was derived from a molecule that plants use to handle inflammation, but with a different molecular pathway than existing anti-inflammatories. The company uses AI models trained on biological data to search for potentially therapeutic compounds and refine them into drugs. The company aims to complete its first clinical trial by the beginning of the second quarter next year.
Key takeaways:
- Insilico Medicine announced results from a clinical trial of ISM001-055, a drug designed using generative AI to treat idiopathic pulmonary fibrosis. The majority of side effects were mild or moderate, and patients who received the highest dose saw improvement in lung function and quality of life.
- Enveda has begun clinical trials of ENV-294, an oral inflammatory agent for the treatment of atopic dermatitis. The drug was derived from a molecule that plants use to handle inflammation, using AI models trained on biological data.
- A study using 17 years of data found that people diagnosed with alcohol use disorder and either obesity or Type 2 diabetes who were taking certain GLP-1 medications experienced reduced alcohol consumption and were less likely to be hospitalized for alcohol-related issues.
- Several healthcare companies announced new deals and updates, including FDA approval for Johnson & Johnson’s Varipulse system for the treatment of atrial fibrillation, and a collaboration between Novartis and Schrödinger to use the latter’s computational discovery platform to develop multiple drugs.